3 Reasons Royalty Pharma Is A Dividend Stock You Never Ha…

The cash Royalty Pharma provides allows drug companies to continue their research efforts in a cost-effective manner. The cash that Royalty Pharma generates from its royalty portfolio funds the cash distributions it pays to holders. Royalty Pharma’s yield is currently around 1.5%, slightly higher than the pharmaceutical sector’s average of roughly 1.4%. Here are three big reasons why even the most conservative dividend investors should take a closer look at Royalty Pharma.

1. The big picture: healthcare is resilient

It is important to understand Royalty Pharma’s role in the broader healthcare sector, as it provides the funding drug companies need to continue developing new drugs. However, it is equally important to remember the role of healthcare for end customers. The drugs that Royalty Pharma owns royalties on help people live better lives. In some cases, they may even be the difference between life and death. Healthcare spending simply isn’t optional most of the time.

So, even in a recession, healthcare spending tends to remain strong. This makes Royalty Pharma the type of investment you can comfortably hold through the entire economic cycle.

2. Royalty Pharma is run by industry experts

There are any number of drug companies you could buy that would let you benefit from the resilient demand for healthcare. But which ones should you buy? That’s actually a pretty difficult question to answer given the complexity and competition in the pharmaceutical sector. If you aren’t an industry expert, you may not have the time or desire to do the legwork necessary to sort the wheat from the chaff.

RPRX – Royalty Pharma Plc

$63.30+$1.15 (+1.84%)

NASDAQ · As of 10:26 AM ET 10/22/26

Premium Feature

Moneyball Superscore78/100

Key data points

Market capMarket cap calculated using publicly traded s outstanding only. Does not include unlisted, private, or dual-class non-traded s. Implied market cap may vary.$27.67B

Day’s range$62.34 – $63.45

52wk range$35.92 – $64.38

Volume269.9K

Avg volume3M

Gross margin99.81%

Dividend yield1.49%

Don’t worry, you aren’t alone. Investing is a lot of work in general, and even more work if you look at highly technical sectors. But Royalty Pharma has you covered since it employs industry experts to help it decide which drugs have the best prospects for success. Simply put, you don’t need to be a pharma expert; you can just buy Royalty Pharma and let the company do all the hard work for you. And, notably, that means keeping up and adjusting to new developments in the sector so the company’s royalty portfolio remains at the cutting edge.

3. Royalty Pharma’s royalty portfolio is diversified

The hard work is deciding which drugs to invest in. But there’s an interesting twist with Royalty Pharma because it doesn’t just work with one company. And its business isn’t totally reliant on just one drug, as are many smaller, and even some larger, drug companies.

Royalty Pharma’s portfolio includes 35 approved products and 16 that are still in development. A full 16 of its drugs generate more than $1 billion in annual revenue, making them “blockbuster” drugs, with an average remaining royalty duration of around 13 years. Royalty Pharma gives you broad exposure to the drug sector with a single investment. If you believe diversification is important for your stock portfolio, then this inherently diversified, dividend-paying drug stock will be right up your alley.

Royalty Pharma checks a lot of boxes

Royalty Pharma isn’t perfect. Just any other pharma company, it will invest in drugs that don’t work out as well as planned. However, when you step back, it provides investors with a reliable income stream in a highly resilient sector. And given the inherent complexity of the pharma sector, management’s expertise and the diversification built into the business model make it an easy solution for investors who want drug exposure but aren’t quite sure where to begin. If you aren’t a drug industry expert, Royalty Pharma could be the one drug stock you buy and never have to sell.

Read Next

Oct 1, 2026 •By Thomas Niel

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs — Is the Stock a Buy?

Sep 24, 2026 •By Reuben Gregg Brewer

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?

Oct 22, 2026 •By Sarah Sidlow

Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility

Oct 22, 2026 •By Sarah Sidlow

Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?

Oct 22, 2026 •By RJ Fulton

Big Pharma vs. Breakthrough Biotech: Which ETF Has More Upside for Investors?

Oct 22, 2026 •By Keith Noonan

Is USA Rare Earth Stock a Once-in-a-Generation Reshoring Opportunity?

About the Author

Reuben Gregg Brewer is a contributing Motley Fool stock market analyst covering energy, utilities, REITs, and consumer staples. He is the former director of research at Value Line Publishing, where he rose from mutual fund analyst to equity analyst before leading all research operations. Reuben holds a bachelor’s degree in psychology from SUNY Purchase, a master’s in social work from Columbia University, and an MBA from Regis University. He has been featured as a financial expert on CNBC and in the Financial Times, Barron’s, and InvestmentNews.

TMFReubenGBrewer

Stocks Mentioned

Motley Fool Stock Advisor’s Latest Pick

Get Access

—% Avg Return

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.